To assess how the availability of glucagon-like peptide-1 receptor agonists (GLP-1RAs) has shifted clinical approaches to obesity management within that population, researchers analyzed records from more than 204,000 13- to 25-year-olds treated for obesity between May 2022 and January 2026 in Epic Cosmos, a U.S.-based electronic health record database
Most people who follow a program maintain more than ten percent of their weight post-therapy
The platform tends to skew younger, more male, and more U.S.-based than the broader population of people taking GLP-1 medications
The question is not simply how much weight you can lose
After observing the weight loss benefits in diabetes patients, other GLP-1s were developed and approved specifically to treat obesity
Equinox, the privately held luxury chain, debuted its GLP-1 Protocol in early 2024, a personal training and nutrition system designed specifically for clients on weight-loss medications